Seamless Therapeutics is a gene editing company based in Dresden, Germany, specializing in recombinases. Led by Co-Founders Anne-Kristin Heninger and Felix Lansing, the company aims to revolutionize gene therapy. They focus on developing a platform for precise gene editing to address severe diseases. Their team includes experienced professionals like Arturo Urrios and advisors such as Prof. Frank Buchholz. With $12.5M seed financing, they're advancing their transformative gene editing platform. Seamless Therapeutics fosters a collaborative work environment and invites skilled individuals to contribute to their mission. They prioritize innovation and precision in their approach to gene editing technologies.